potential COVID-19 treatments living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 hospitalized
	COVID 19 hospitalized	COVID 19 all comers	COVID-19 mild to moderate	COVID-19 severe or critically
potential COVID-19 treatments
adjuvant therapies
anticoagulant			X-COVID-19
anticoagulant, curative dose	COALIZAO ACTION		ATTACC, ACTIV-4a, and REMAP-CAP ...	REMAP-CAP, ACTIV-4a, ATTACC ... COVID-PACT
anticoagulation, intermediate prophylactic dose				INSPIRATION
heparin at therapeutic dose			RAPID ...	ATTACC ... ACTIV-4a ... REMAP-CAP Anticoagulation
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
mavrilimumab	MASH-COVID ...
clarithromycine			Rashad ...
colchicine	COLCOVID Lopes MIF Salehzadeh GRECCO-19 RECOVERY ... Horby		COL-COVID ...	COLCHIVID
Colchicine plus rosuvastatin	COLSTAT Gaitan-Duarte ...
non-steroidal anti-inflammatory drugs			Guzman-Esquivel
Indomethacin			Ravichandran
stem cells	Lanzoni Carmenate ...			Shu Shi
vilobelimab (IFX-1)				PANAMO
corticosteroids	GLUCOCOVID
dexamethasone	RECOVERY dexamethasone			DEXA-COVID19 CODEX ... Jamaati Rashad Naik
Dexamethasone 12mg				COVID STEROID 2
Hydrocortisone				CAPE-COVID REMAP-CAP, fixed 7-day course REMAP-CAP, shock-dependent course Munch ...
methylprednisolone	Tang X Metcovid Ranjbar			Steroids-SARI Edalatifard Farahani
Immunostimulants drugs
convalescent plasma treatment	ConCOVID ... ConPlas-19 COP-COVID-19 CONTAIN COVID-19 PC/COVID-19 NCT04397757 PLACO-COVID CONCOR-1 CPC-SARS NCT04442191 DAWN-Plasma NCT04385199 COPLA-II trial NCT04403477 ... ASCOT RECOVERY ... CONFIDENT PERUCONPLASMA Bennett-Guerrero Salman Kirenga LACCPT Co-CLARITY NCT04528368 Holm K CCAP-2 Baldeon Menichetti	LIFESAVER	PLACID Libster	CP-COVID-19 ILBS-COVID-02 ... Li Rasheed O’Donnell PlasmAr CAPSID AlQahtani REMAP-CAP ... RECOVER PICP19 ... Pouladzadeh Sekine ... Ray
Early convalescent plasma.	Balcells
immunoglobulin therapy	Sakoulas Parikh			Tabarsi Gharebaghi Raman
interferon
IFN beta-1a	SOLIDARITY ...			Davoudi-Monfared Darazam ... Kalil ...
high-dose IFN beta-1a	Darazam
IFN beta-1b				Rahmani Darazam ...
IFN gamma	Esquivel-Moynelo
inhaled interferon
IFN alpha
pegylated interferon-α2b			Pandit Shashi Bhushan
recombinant super-compound interferon rSIFN-co	Li
SNG001 inhaled interferon beta	Synairgen SG016 SPRINTER
interferon / TFF2			Fu
peginterferon			Jagannathan
PNB001			Lattmann
neutralizing antibody	ITAC
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)	ACTIV-3 ...
bamlanivimab monotherapy	ACTIV-3/TICO LY-CoV555
casirivimab/imdevimab (Ronapreve)	RECOVERY ...		Somersan-Karakaya ...
cilgavimab and tixagevimab (Evusheld)	ACTIV-3/TICO ...
equine polyclonal antibodies INM005				Lopardo
sotrovimab (Xevudy; VIR-7831)	ACTIV-3/ TICO ...
Immunosuppressants drugs
abatacept				ACTIV-1 abatacept
adalimumab				Fakharian
anakinra	SAVE-MORE		CORIMUNO-ANA-1
anti-interleukin-6
Levilimab				V.Lomakin ...
sarilumab	CORIMUNO-SARI-1 ...			sarilumab Sanofi phase 3 US sarilumab Sanofi phase 3 outside US REMAP-CAP sarilumab
sarilumab high dose (400mg)		sarilumab phase 2 high dose		Lescure ...
sarilumab low dose (200mg)		sarimulab phase 2 low dose		Lescure ...
tocilizumab	Dongsheng Wang RCT-TCZ-COVID-19 EMPACTA RECOVERY Soin AS ... Rutgers NCT04412772 ... Declercq J ... NCT04577534 ... EU-CTR2020-001375-32 ... EU-CTR2020-001748-24 ... NCT04479358 ... NCT04434717 ...	TOCOVID BACC Bay Tocilizumab Trial		MARIPOSA COVACTA ... CORIMUNO-TOCI-1 ... REMAP-CAP ... Veiga Rashad Talaschian Hamed CORIMUNO-TOCI-ICU ... NCT04377750 ... Rosas ... Sarhan Sarhan
canakinumab	Sheng ...			CAN-COVID
cenicriviroc				ACTIV-1 cenicriviroc
infliximab				ACTIV-1 infliximab
itolizumab				Kumar
janus kinase (JAK) inhibitor
baricitinib	COV-BARRIER ACTT-2 ...	RECOVERY		COV-BARRIER ...
ruxolitinib				Cao DEVENT
TD-0903
TD-0903 10mg				Singh ...
TD-0903 1mg				Singh ...
TD-0903 3mg				Singh ...
tofacitinib	STOP-COVID ...		Murugesan
lenzilumab			LIVE-AIR ...
tacrolimus				TACROVID
thalidomide				Amra
Kinase inhibitors
acalabrutinib	CALAVI CALAVI US
imatinib			Covid-19 HUF	Aman
leflunomide	Wang et al.	Wang
statins
Atorvastatin				INSPIRATION-S
antiandrogenic
progesterone			Ghandehari
proxalutamide	Cadegiani
antiviral and associated therapy
azithromycin	Sekhavati RECOVERY ...		COALITION I Covid-19 Brazil ... Rashad A ...	COALITION II Covid-19 Brazil ...
azvudine			Ren
baloxavir marboxil	Lou Y
bromhexine	Ansarin Tolouian		Li T
chloroquine and derivatives
chloroquine	Huang	Chen, ChiCTR2000030054 - Chloroquine	NCT04342650
hydroxychloroquine	Tang HAHPS ORCHID Duke University hydroxychloroquine/azithromycine RECOVERY SOLIDARITY ... Chen NO COVID-19 ... Abd-Elsalam CCAP-1 Duke university HCQ ARCHAIC -hydroxychloroquine PROTECT B TEACH OAHU-COVID19 HYCOVID IRCT20200428047228N1 // U07 Gonzalez ... PROTECT A	ChiCTR2000030054-HCQ ... IRCT20150808023559N20 IRCT20150808023559N20 NOR-Solidarity ...	HC-nCoV ... Zhaowei Chen Coalition Covid-19 Brazil I ... NCT04333654 FACCT Trial Dubee Kamran	REMAP-CAP-HCQ HYDRA ... Sarhan Sarhan
darunavir cobicistat		Jun C
Emtricitabine/tenofovir plus colchicine plus rosuvastatin	Gaitan-Duarte ...
Ensitrelvir (XOCOVA)			Mukae - Phase 2a
favipiravir	IRCT20200428047228N1 // U07 Udwadia AVIFAVIR	Lou ... Chang Chen et al. NCT04310228-FAVI ... jRCTs041190120 IRCT20150808023559N20 IRCT20150808023559N20	Dabbous HM Holubar M IRCT20151227025726N14 // U07 FACCT Trial Udwadia AVIFAVIR Shenoy S NCT04542694 Ruzhentsova T Solaymani-Dodaran Shinkai
favipiravir plus interferon			Khamis
hydroxychloroquine plus macrolides	Duke university HCQ-AZI
azithromycin plus hydroxychloroquine	ProPAC-COVID		Coalition Covid-19 Brazil I ...
ivermectin	Gonzalez ...		Shahbaznejad Ahmed Chachar Chaccour Bukhari Kirti Babalola RIVET-COV ... Abd-Elsalam Krolewiecki I-TECH ... Mayer	Okumuş Galan Galan
ivermectin plus doxycycline	Hashim A		NCT04523831 ...
lopinavir/ritonavir	RECOVERY SOLIDARITY ... Nojomi Ader ...		ELACOI ...	Cao REMAP-CAP ...
Lopinavir/ritonavir plus hydroxychloroquine				REMAP-CAP ...
lopinavir/ritonavir plus interferon ß-1a	Ader ...
lopinavir/ritonavir, ribavirin and interferon beta-1b			Hung et al.
niclosamide	Abdulamir
nirmatrelvir / ritonavir (Paxlovid)		EPIC-SR
nitazoxanide			Rocco Silva Fontanesi
opaganib	Winthrop
remdesivir	NIH NIAID ACTT-1 DisCoVeRy ... SOLIDARITY ... Mahajan	Norwegian NOR study ... Andreas ...	GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ...	CAP-China ...
sofosbuvir	Sali Alavi-moghaddam
sofosbuvir and daclatasvir	Sadeghi Yakoot Mobarak S ... Mobarak ...
sofosbuvir and ledipasvir	Elgohary		Nourian A
tenofovir/emtricitabine	Gaitan-Duarte ...
umifenovir (arbidol)	UAIIC Nojomi	ELACOI ...	Yethindra ELACOI ...
zinc	Patel
Drugs for acid related disorders
H2 blockers
famotidine	Samimagham
miscellaneous
alpha lipoic acid				Ming Zhong
Aspirin	RECOVERY ...
aviptadil		COVID-AIV		ACTIV-3 Critical Care
camostat mesilate		Gunst JD
Cannabidiol			Crippa ...
honey	Silveira
povidone-iodine	Mohamed
pyridostigmine				Fragoso-Saavedra ...
sabizabulin			VERU-111
Oral antidiabetic drugs
dapagliflozin	DARE-19
DPP-4 inhibitor	Guardado-Mendoza			Abuhasira
Renin-angiotensin-system-acting agents
angiotensin receptor blockers (ARBs)	Duarte Nouri-Vaskeh
losartan		University of Minnesota
discontinuation of ACEI/ARB	REPLACE Najmeddin		Lopes ...
Vitamins
vitamin C				Zhang Jamali Moghadam Siahkali Kumari
Vitamin D	Entrenas ... Murai		Rastogi	COVID-VIT-D
hight dose vitamin D			COVIT-TRIAL

60 studies excluded by filtering options 1

5092	Yang, 2020	1	13	3		not a RCT	high risk of bias
5228	Bean, 2020	1	19	3		not a RCT	high risk of bias
5295	Zhang, 2020	1	13	3		not a RCT	high risk of bias
5331	Li, 2020	1	13	4		not a RCT	high risk of bias
5332	Meng, 2020	1	13	4		not a RCT	high risk of bias
5345	Yan et al., 2020	1	20	4		not a RCT	high risk of bias
5346	Mancia, 2020	1	20	3		not a RCT	high risk of bias
5347	Mehra, 2020	2	12	4	excluded	not a RCT	high risk of bias
5348	Reynolds (COVID positive patient), 2020	1	13	3		not a RCT	high risk of bias
5349	Reynolds (prophylaxis), 2020	1	13	3		not a RCT	high risk of bias
5370	Khera (outpatients), 2020	1	13	3		not a RCT	high risk of bias
5372	Khera (inpatients), 2020	1	13	3		not a RCT	high risk of bias
5399	Northwell Consortium (Richardson), 2020	0	99	0	selection pending
5440	Morales, 2020	1	13	0		not a RCT	risk of bias not avaialble
5604	Schneeweiss, 0	0	13	0	selection pending
5605	Vila-Corcole, 0	0	13	0	selection pending
5619	Pan, 2020	0	13	0	selection pending
5797	Rossi, 0	0	13	0	selection pending
5903	Anzola, 2020	0	10	0	selection pending
6660	Bae, 2021	0	12	0	selection pending
6729	Shah, 2021	1	13	3		not a RCT	high risk of bias
6788	Waissengrin, 2021	0	13	0	selection pending
6790	Pawlowski, 2021	1	13	0		not a RCT	risk of bias not avaialble
6894	Andrejko, 2021	1	20	0		not a RCT	risk of bias not avaialble
6927	Rossman, 2021	0	13	0	selection pending
6931	Yair, 2921	1	32	0		not a RCT	risk of bias not avaialble
6934	Boyarsky, 2021	1	32	0		not a RCT	risk of bias not avaialble
6949	Pawlowski, 2021	1	13	0		not a RCT	risk of bias not avaialble
6981	Public Health England (Harris), 2021	1	13	3		not a RCT	high risk of bias
7025	Haberman, 2021	0	13	0	selection pending
7070	PHE variants (Technical briefing 12 22 may 2021), 2021	2	20	2	excluded	not a RCT
7325	Skowronski, 2021	0	13	0	selection pending
7419	Scotland delta (Sheikh), 2021	1	20	3		not a RCT	high risk of bias
7420	PHE (Stowe), 2021	2	13	3	excluded	not a RCT	high risk of bias
7950	Harris, 2021	1	13	3		not a RCT	high risk of bias
8143	Butt, 2021	1	20	2		not a RCT
8147	Canada (Nasreen), 2021	1	20	2		not a RCT
8149	PHE Technical briefing 16 (11/18 June 2021), 2021	2	13	3	excluded	not a RCT	high risk of bias
8150	Ramasamy, 2021	0	32	0	selection pending
8164	Public Health England, May 16, 2021 (Bernal), 2021	1	20	2		not a RCT
8255	REACT-SCOT, 2021	1	20	0		not a RCT	risk of bias not avaialble
8272	Martinez-Baz, 2021	1	13	0		not a RCT	risk of bias not avaialble
8274	REACT-1 round 13 final report (Elliott, Imperial College London), 2021	1	13	3		not a RCT	high risk of bias
8275	Musser, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8294	CDC Mesa County, Colorado, 2021	1	13	3		not a RCT	high risk of bias
8313	Bahl (Fully vaccinated vs unvaccinated), 2021	0	10	0	selection pending
8350	Rosenberg, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8359	Oxford (Pouwels), 2021	1	13	2		not a RCT
8360	HEROES-RECOVER (Fowlkes), 2021	1	13	3		not a RCT	high risk of bias
8513	Grannis, 2021	1	20	3		not a RCT	high risk of bias
8514	VA (Bajema), 2021	1	20	3		not a RCT	high risk of bias
8515	Scobie, 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9170	UKHSA report 33 (23 december 2021), 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9176	UKHSA 31 december 2021, 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9214	Southern California (Lewnard), 2022	2	13	0	excluded	not a RCT	risk of bias not avaialble
9216	Sultan, 2022	0	12	0	selection pending
9267	Ostropolets, 2021	0	12	0	selection pending
9294	UKHSA (report W4- 27 January), 2022	2	12	0	excluded	not a RCT	risk of bias not avaialble
9491	Li X, 2022	1	12	0		not a RCT	risk of bias not avaialble
9590	UKHSA report week 12 (24 March 2022), 2022	1	12	0		not a RCT	risk of bias not avaialble